Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Down 14.5%, Is Pfizer Stock a Screaming Buy?

TheMotleyFool

0 0

Down 14.5%, Is Pfizer Stock a Screaming Buy?Photo, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

As the major U.S. stock indices fell into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors -- in many cases thanks to their largely recession-proof business models, reliable cash flows, and dependable quarterly dividends.

AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year: